GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers
February 07, 2023 09:00 ET
|
GeoVax, Inc.
Phase 1/2 Trial Now Active at Stanford, Emory, and Thomas Jefferson Universities ATLANTA, GA, Feb. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax to Present at the 2023 BIO CEO & Investor Conference
January 26, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Receives Notice of Allowance for Zika Vaccine Patent
January 25, 2023 11:00 ET
|
GeoVax, Inc.
Preclinical Evaluation Demonstrated 100% Protection Against a Lethal Dose of Zika Virus ATLANTA, GA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023
January 04, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax
December 20, 2022 09:00 ET
|
GeoVax, Inc.
First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) --...
GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors
December 07, 2022 16:00 ET
|
GeoVax, Inc.
Dr. Morgan Brings Extensive COVID-19, Medical and Healthcare Management Expertise ATLANTA, GA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022
November 28, 2022 10:15 ET
|
GeoVax, Inc.
Presentation to Focus on Progress of Pan-Coronavirus (Universal) Vaccines to Protect Against Evolving Variants ATLANTA, GA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc....
GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update
November 09, 2022 16:00 ET
|
GeoVax, Inc.
Phase 2 Clinical Trials Advance for COVID-19 and Immuno-Oncology Company Secures Rights to NIH-MVA for Protection Against Monkeypox and Smallpox ATLANTA, GA, Nov. 09, 2022 (GLOBE NEWSWIRE) --...
GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022
October 26, 2022 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and...
GeoVax to Present at Vaccines Summit-2022
October 11, 2022 09:00 ET
|
GeoVax, Inc.
Presentation to Focus on Development of Pan-Coronavirus (Universal) Vaccines to Protect Against Evolving Variants ATLANTA, GA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....